Nongenomic signaling of the retinoid X receptor through binding and inhibiting Gq in human platelets

Moraes, L. A., Swales, K. E., Wray, J. A., Damazo, A., Gibbins, J. M. ORCID: https://orcid.org/0000-0002-0372-5352, Warner, T. D. and Bishop-Bailey, D. (2007) Nongenomic signaling of the retinoid X receptor through binding and inhibiting Gq in human platelets. Blood, 109 (9). pp. 3741-3744. ISSN 0006-4971 doi: 10.1182/blood-2006-05-022566

Abstract/Summary

Retinoid X receptors (RXRs) are important transcriptional nuclear hormone receptors, acting as either homodimers or the binding partner for at least one fourth of all the known human nuclear receptors. Functional nongenomic effects of nuclear receptors are poorly understood; however, recently peroxisome proliferator-activated receptor (PPAR) gamma, PPAR beta, and the glucocorticoid receptor have all been found active in human platelets. Human platelets express RXR alpha, and RXR beta. RXR ligands inhibit platelet aggregation and TXA(2) release to ADP and the TXA(2) receptors, but only weakly to collagen. ADP and TXA(2) both signal via the G protein, Gq. RXR rapidly binds Gq but not Gi/z/o/t/gust in a ligand-dependent manner and inhibits Gq-induced Rac activation and intracellular calcium release. We propose that RXR ligands may have beneficial clinical actions through inhibition of platelet activation. Furthermore, our results demonstrate a novel nongenomic mode for nuclear receptor action and a functional cross-talk between G-protein and nuclear receptor signaling families. (C) 2007 by The American Society of Hematology.